A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
This study has been terminated.
Sponsor:
Endo Pharmaceuticals
Information provided by (Responsible Party):
Endo Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01314664
First received: March 11, 2011
Last updated: February 14, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.
| Condition |
|---|
|
Bladder Cancer CIS |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) |
Resource links provided by NLM:
Genetics Home Reference related topics:
bladder cancer
Drug Information available for:
Valrubicin
U.S. FDA Resources
Further study details as provided by Endo Pharmaceuticals:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
subjects who will be receiving intravesical valrubicin treatment for NMIBC
Criteria
Inclusion Criteria:
- Males and females 18 years of age and older
- Diagnosed with NMIBC
- Prescribed intravesical valrubicin to treat NMIBC
- Understood and signed Informed Consent to participate
Exclusion Criteria:
- None
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314664
Locations
| United States, Arizona | |
| BCG Oncology | |
| Phoenix, Arizona, United States, 85032 | |
| United States, Florida | |
| Urology Research Network | |
| Hialeah, Florida, United States, 33149 | |
| Advanced Urology Association of Florida | |
| Vero Beach, Florida, United States, 32960 | |
| United States, Kansas | |
| Kansas City Urology Care | |
| Overland Park, Kansas, United States, 66211 | |
| United States, New Jersey | |
| Delaware Valley Urology | |
| Sewell, New Jersey, United States, 08080 | |
| Delaware Valley Urology | |
| Voorhees, New Jersey, United States, 08043 | |
| United States, New York | |
| Long Island Urological Associates | |
| Bethpage, New York, United States, 11714 | |
| United States, Pennsylvania | |
| Urologic Consultants of SE PA | |
| Bala-Cynwyd, Pennsylvania, United States, 19004 | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| Urology Associates of North Texas | |
| Arlington, Texas, United States, 76017 | |
| Urology Clinics of North Texas | |
| Dallas, Texas, United States, 75231 | |
Sponsors and Collaborators
Endo Pharmaceuticals
More Information
No publications provided
| Responsible Party: | Endo Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01314664 History of Changes |
| Other Study ID Numbers: | EN3329-402 |
| Study First Received: | March 11, 2011 |
| Last Updated: | February 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Endo Pharmaceuticals:
|
Non-Muscle Invasive Bladder Cancer CIS BCG Refractory |
Additional relevant MeSH terms:
|
Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Urinary Bladder Diseases |
Urologic Diseases Valrubicin Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013